Takeda Head Blames Own Structural Problems For Foreign Drug Delays
This article was originally published in PharmAsia News
Executive Summary
Takeda's president says structural differences among pharmaceutical companies from different countries, including Japan, are responsible for approval delays faced by many drug makers in the United States. Yasuchika Hasegawa said his own company is analyzing its responsibility in the delays, and plans discussions with U.S. FDA about approval timelines and details of clinical trials as part of an effort to correct Takeda's structural deficiencies. Astellas Pharma and Daiichi Sankyo are other major Japanese drug makers that have complained about delays hampering their plans for expansion abroad. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.